Biogen Idec (NASDAQ:BIIB) traded today at a new 52-week high of $177.91. So far today approximately 659,000 shares have been exchanged, as compared to an average 30-day volume of 1.3 million shares.
Biogen Idec Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company's products addresses diseases such as multiple sclerosis, non-Hodgkin's lymphoma, rheumatoid arthritis, crohn's disease, and psoriasis.
In the past 52 weeks, shares of Biogen Idec have traded between a low of $118.52 and a high of $177.91 and are now at $176.98, which is 49% above that low price. Over the past week, the 200-day moving average (MA) has gone up 0.4% while the 50-day MA has advanced 1.1%.
Based on a current price of $176.98, Biogen Idec is currently 0.2% above its average consensus analyst price target of $176.55. Biogen Idec shares have support at the 50-day moving average (MA) of $157.57 and additional support at the 200-day MA of $148.33.